priority review Archives

Tag: priority review

LRA Statement: Potential Lupus Nephritis Drug Voclosporin Granted Priority Review by the U.S. FDA

NEW YORK, NY. July 22, 2020. The Lupus Research Alliance congratulates Aurinia Pharmaceuticals Inc. on acceptance of its NDA filing and priority review designation by the U.S. Food and Drug Administration for its investigational drug voclosporin for lupus nephritis. A serious inflammation of the kidneys, lupus nephritis is one of the most common complications of […] Read More

Aurinia Completes NDA and Requests Priority Review of Voclosoporin by FDA for Lupus Nephritis

May 28, 2020 The Lupus Research Alliance is pleased to share that Aurinia Pharmaceuticals Inc submitted a New Drug Application (NDA) to the U.S. FDA for voclosporin as a potential treatment for lupus nephritis with request for a priority review. Lupus nephritis is one of the most common complications of systemic lupus erythematosus, a serious […] Read More